© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
editorial |
Where is the future of endometrial cancer therapy?
Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK, USA
* (E-mail: scott-mcmeekin@ouhsc.edu)
| The first 150 words of the full text of this article appear below. |
Chemotherapy has moved into the forefront of management of endometrial cancer. In the setting of metastatic disease or nonlocal recurrence, traditionally, progestational agents and chemotherapy have been viewed as the most appropriate treatment options. What is different today is chemotherapy is increasingly integrated into the first-line therapy of patients with small-volume residual advanced disease [1, 2] and early-stage high-risk disease [3–5]. In this journal, Ang et al. [6] present the results of a provocative phase II/feasibility trial evaluating patients with advanced or recurrent endometrial carcinoma or uterine or ovarian carcinosarcoma. Building on previous studies which have identified doxorubicin, paclitaxel, and platinum as active components in combination regimens [7, 8], the authors assessed the feasibility of administering sequential doublet therapy with carboplatin/paclitaxel and carboplatin/doxorubicin. In considering the future direction in the management of patients with advanced endometrial cancer, the
what are the best cytotoxic agents in endometrial cancer?
what is the role of radiation therapy in advanced disease?
is ovarian cancer the right model?
where do we go from here?
funding
disclosure